The East-West Bio Brief
China & Asia biotech, for investors. A daily five-minute brief, Tuesday to Friday, and a longer weekly episode every Monday. Hosted by Basil Lui and Ning.
Episodes
Each episode page has the full transcript, every source linked, and plain-English explanations of the drugs we cover.
-
Daily, Tue 3 Nov: Fresenius–WuXi biosimilars, uniQure Huntington's FDA date, Vaxcell liver cancer
Today on The East-West Bio Brief daily, Basil Lui and Ning cover Fresenius's exclusive deal with WuXi Biologics for up to 37 biosimilars, starting with copies of Roche's Polivy and Amgen's Tepezza; Burgeon's Series A-plus for a non-steroid…
-
Daily, Mon 2 Nov: A Chinese cancer drug wins on survival, AI drug designers raise, a Korean licence
Today on The East-West Bio Brief daily, Basil Lui and Ning cover a China-only trial at ESMO where Akeso's ivonescimab plus chemo beat AstraZeneca's durvalumab plus chemo on survival in first-line biliary tract cancer; three China rounds in…
-
Pilot: Asia biotech, decoded for investors
In the first episode of The East-West Bio Brief, Basil Lui and Ning read China's primary sources and translate them into what they mean for deals. We cover Beijing's draft export controls on biotech platforms (comments close 15 Nov), new…
About the show
Over half of global biotech licensing value now comes from China, and the first signal usually shows up in Chinese. Basil Lui and Ning read those primary sources in the original and turn them into what matters for deals: who's licensing what, how much is real upfront cash, and where the next wave is coming from across Hong Kong, Singapore, Korea, Japan and Southeast Asia.
Tuesday to Friday, a five-minute daily brief on the funding rounds, listings, trial results and approvals that matter, with every drug explained in plain English. Every Monday, a longer weekly episode that connects the dots, plus a segment on East-West deep tech.
Our aim is simple: help BD teams, VCs, crossover funds and family offices spot what's coming out of Asia early, from sourced facts rather than hype.
Full transcripts and sources for every episode arrive each Sunday in The East-West Bio Brief newsletter on LinkedIn. Subscribe here: The East-West Bio Brief newsletter on LinkedIn
Our voices are AI-generated from our own; the views and research are ours. Personal views, not investment advice.